Advances in solid state formulation

Advanced techniques are required to characterise the stability, performance and manufacturability of complex dry powders for inhalation, from small molecules to biological entities. This session will present advances in solid-state characterisation, providing deeper mechanistic insight into these materials and their performance.

Inhaled Antimicrobials and Vaccines

This session will explore innovative nasal and orally inhaled aerosol medicines for preventing and treating respiratory infections. We will showcase emerging delivery technologies and translational approaches for targeting antimicrobials and vaccines to the respiratory tract and achieving effective biological responses.

Digital Drug Delivery to the Lungs (dDDL)

Automation, modelling and AI are transforming lung drug development, with many stages becoming increasingly prediction-driven. This session will explore how these technologies are disrupting drug delivery to the lungs, the challenges they present, and what the future may hold.

Site‑Specific Aerosol Delivery

This session will explore technologies for precise, region-specific aerosol delivery within the nasal cavity and lungs. Presentations will highlight advances in device design, engineered formulations, inspiratory manoeuvres, modelling and trajectory control to enhance targeted deposition and personalise inhaled therapies.

Propellants, planet & patients: clinical needs and advocacy

With the first products using new propellants now approved and increasing regulatory pressures, this session will address recent changes affecting the MDI and the innovations required to ensure that it continues to meet the clinical needs of our patients into the future.

The DDL Incubator

 A new session dedicated to exploring the funding options available to start-ups, biotech founders and similar stakeholders. Immersive presentations from industry recognised experts will cover four key topics: grants, bootstrapping, venture capital and corporate partnerships, explaining what ‘investor ready’ really means.